Clinical Fellowships for ATTR Amyloidosis
Forecasted
Clinical Fellowships for ATTR Amyloidosis supports institutional programs that train physicians in disease diagnosis, treatment, and research to improve early recognition and patient-centered care.
Funder: Alnylam Pharmaceuticals
Due Dates: 2027–2028 academic year: Closed | Spring 2027: Details for 2028–2029 expected | Requests: At least 45 days before program start
Summary: Supports institutional clinical fellowship programs advancing physician training in the diagnosis, treatment, and research of ATTR amyloidosis.
Key Information: Only eligible organizations or entities may receive funding; individuals cannot apply or receive awards.
Description
Alnylam Pharmaceuticals supports educational clinical fellowship programs within healthcare academic organizations through its Clinical Fellowships for ATTR Amyloidosis program. Funding supports programs that mentor physicians and advance their training in the diagnosis, treatment, and research of Transthyretin (ATTR) Amyloidosis.
The program emphasizes multidisciplinary collaboration to improve early recognition of the disease and optimize treatment pathways. It also seeks to accelerate the translation of emerging science into high-quality, patient-centered care. Requesting institutions must demonstrate the infrastructure, expert faculty, and curriculum needed to design and conduct a successful fellowship program.
